Table 2.
Patient baseline and demographic characteristics.
| Free-dose combination group N = 293 | Fixed-dose combination group N = 366 | Total N = 659 | |
|---|---|---|---|
| Age, years | 62.0 (9.6) | 61.9 (8.7) | 61.9 (9.1) |
| 60–75, n (%) | 141 (48.1) | 192 (52.5) | 334 (50.5) |
| >75, n (%) | 23 (7.8) | 16 (4.4) | 39 (5.9) |
| Gender, men, n (%) | 152 (51.9) | 205 (56.0) | 360 (54.4) |
| Body mass index, kg/m2 | 29.6 (3.9) | 30.4 (4.04) | 30.1 (4.0) |
| Duration of T2DM, months | 55.4 (51.1) | 62.4 (55.2) | 59.6 (54.2) |
| Mean HbA1c, % | 7.9 (0.8) | 8.1 (0.9) | 8.0 (0.8) |
| Comorbidity, yes, n (%) | 54 (18.4) | 49 (13.4) | 104 (15.7) |
| Concomitant treatments, yes, n (%) | 28 (9.6) | 31 (8.5) | 60 (9.1) |
T2DM, type 2 diabetes mellitus; data are presented as mean (SD) unless otherwise specified.